Barry Douglas
Known title: General CounselCIK: 0001890662
Associated companies
Transaction History
| TNGX | ▼ Sell | Open Market | 2,556 | $8K | 2/5/2025 | View on chart |
| TNGX | ▼ Sell | Open Market | 2,774 | $8K | 2/4/2025 | View on chart |
| TNGX | ▲ Buy | Grant | 27,363 | $0 | 2/3/2025 | View on chart |
| TNGX | ▼ Sell | Open Market | 1,354 | $17K | 2/7/2024 | View on chart |
| TNGX | ▼ Sell | Open Market | 1,422 | $18K | 2/6/2024 | View on chart |
| TNGX | ▲ Buy | Grant | 22,859 | $0 | 2/1/2024 | View on chart |
| TNGX | ▲ Buy | Grant | 23,898 | $0 | 3/1/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026
Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.
Tango Therapeutics to Present Phase 1/2 Vopimetostat Data at ESMO 2026. Tango Therapeutics announced that it will share updated results from its Phase 1/2 study of vopimetostat combined with daraxonrasib or zoldonrasib in patients with MTAP‑deleted/RAS‑mutated metastatic pancreatic cancer and non‑small cell lung cancer at the ESMO Congress 2026. The data focus on a targeted patient group and may provide insight into the early‑stage safety and activity of the combination therapies. The stock is currently near a long‑standing support level, which could be monitored as the conference proceeds.